JAX compound evaluation: metabolic disorders
Our In Vivo efficacy testing services combine proven JAX® Mice models of diabetes and obesity with a range of high throughput, cost-effective and non-invasive test platforms for reliable measurements of clinically relevant disease endpoints:
Type 2 diabetes
- Compound efficacy testing in endogenous models of type 2 diabetes
- Models:
- "db" (BKS.Cg-Dock7m +/+ Leprdb/J)
- "ob" (B6.V-Lepob/J)
- TALLYHO/JngJ
- Readouts:
- Body weight
- Blood glucose
- GTT
- ITT
- Blood lipid distribution
- DEXA or QNMR body tissue composition
- Histopathology
- Sample studies:
- Diabetes study design (.pdf)
- Wound healing sample study (.pdf)
Atherosclerosis
- Compound efficacy testing in an endogenous model of atherosclerosis
- Model: B6.129P2-Apoetm1Unc/J
- Readouts:
- Body weight
- Blood lipid composition
- Atherosclerotic lesions
- Quantitative analysis of aortic plaque deposition
Hypertension
- Inbred hypertensive strain to test compound efficacy
- Models:
- BPH/2J (high blood pressure)
- BPN3/J (normal blood pressure)
- Readouts: Tail cuff systolic and dyastolic blood pressure and pulse management
Obesity
- Compound efficacy testing in mouse obesity models
- Models:
- Induced (C57BL/6J mice fed high fat diet)
- Spontaneous (db, ob)
- Readouts:
- Body weight
- Blood glucose
- GTT
- ITT
- Blood lipid distribution
- Metabolic cage monitoring
- DEXA or QNMR body tissue composition
- Histopathology
Hyperlipidemia
- Compound efficacy testing in hyperlipidemic diseases
- Model: B6.129S7-Ldlrtm1Her/J on Western (high cholesterol) diet
- Readouts:
- Body weight
- Blood lipid composition
- Atherosclerotic lesions
- DEXA or QNMR body tissue composition
- Histopathology
